Sunshine Biopharma (SBFM) Net Cash Flow Growth (3y) (2014 - 2026)
Sunshine Biopharma (SBFM) Net Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -62.71% |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | 4.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.95% |
| Dec 31, 2025 | 63.24% |
| Sep 30, 2025 | 11.82% |
| Jun 30, 2025 | -59.87% |
| Mar 31, 2025 | -28.85% |
| Dec 31, 2024 | -77.72% |
| Sep 30, 2024 | -28.23% |
| Jun 30, 2024 | -322.63% |
| Mar 31, 2024 | 24.27% |
| Dec 31, 2023 | -99.77% |
| Sep 30, 2023 | -48.05% |
| Jun 30, 2023 | -35.71% |
| Mar 31, 2023 | -333.87% |
| Dec 31, 2022 | -689.43% |
| Sep 30, 2022 | -200.52% |
| Jun 30, 2022 | 701.49% |
| Mar 31, 2022 | 733.37% |
| Dec 31, 2021 | -92.61% |
| Sep 30, 2021 | 772.24% |
| Jun 30, 2021 | -1.45% |